MEDIA ADVISORY: Baycrest Experts Available During AAIC® 2025 in Toronto
This international gathering offers a timely opportunity to explore the growing impact of dementia on families, economies and health care systems, along with the latest advances in prevention, care, treatment and research.
Dr. Howard Chertkow
Scientific Director, Baycrest's Kimel Family Centre for Brain Health & Wellness
Scientific Director, Canadian Consortium on Neurodegeneration in Aging (CCNA)
Dr. Chertkow is a member of the AAIC Scientific Program Committee and one of Canada's most respected dementia researchers. He is available to speak on topics including dementia detection, prevention, treatment and Canada's role in the global research landscape.
More Baycrest Experts You Can Speak With
Dr. Adriana Shnall, Program Director, Baycrest Koschitzky Centre for Innovations in Caregiving, can speak to innovative tools supporting dementia caregivers, including those in rural and underserved communities. At AAIC, she is co-presenting on the use of virtual reality, AI and other strategies to better support families in community and long-term care settings.
Dr. Allison Sekuler, President & Chief Scientist, Baycrest Academy for Research and Education is available to speak on the rising prevalence of dementia in Canada and its impact on individuals, families and the healthcare system.
Dr. Nicole Anderson, Associate Scientific Director, Baycrest's Kimel Family Centre for Brain Health & Wellness, can discuss the latest in dementia prevention research, including evidence that nearly half of all cases may be preventable.
Baycrest combines world-class care with cutting-edge research to help shape the future of aging and brain health. If you are working on AAIC-related coverage or broader dementia stories, our experts are available for interviews throughout the conference.
Throughout the week, we will share updates with media highlighting key topics, research developments and expert perspectives from Baycrest.
Please contact Natasha Nacevski-Laird, Media Relations Specialist at Baycrest, to schedule an interview.
About Baycrest
At Baycrest, our vision is a world where every older person lives with purpose, fulfilment and dignity. Baycrest is a global leader in aging and brain health innovation, with over 105 years of expertise in seniors' care and cutting-edge research. Baycrest has been Designated with Exemplary Status by Accreditation Canada, and drives industry-leading care and safety outcomes. As the home of the Centre for Aging + Brain Health Innovation (CABHI) powered by Baycrest, the Baycrest Academy for Research and Education (BARE) and the Canadian Consortium on Neurodegeneration in Aging, Baycrest is at the forefront of dementia research. Affiliated with the University of Toronto, Baycrest's training programs shape the future of care globally, while Baycrest Global Solutions extends its expertise to senior living and healthcare internationally. For more information, visit: baycrest.org.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBC
2 days ago
- CBC
Photo project turns lens on young Inuit life in Winnipeg
A new photo project asked 15 young Inuit to document what life in Winnipeg looks like for them. The project, a collaboration between the Tunngasugit Inuit Resource Centre in Winnipeg and the University of Manitoba, aims to address Inuit health and wellness in the city.
CTV News
2 days ago
- CTV News
3 myths about metabolism could be holding you back
Think speeding up your metabolism is key to losing weight? Metabolism has grown into one of the biggest buzzwords in the wellness industry — a tricky code that, if deciphered, is believed to unlock the secrets of weight loss and overall health. Despite the term's ubiquity, one scientist says many people don't understand much of how this basic bodily process works. 'They think it has something to do with how much food we can eat without gaining weight or something like that,' Dr. Kevin Hall told CNN Chief Medical Correspondent Dr. Sanjay Gupta recently on his podcast, Chasing Life. Hall wants to elevate metabolism for different reasons. 'Metabolism is just this incredible biochemical process that basically turns the food that we eat and the oxygen that we breathe into essentially … everything we are and everything we do,' he said. A leading nutrition and metabolism scientist, Hall is well-known for his research on contestants from the reality show 'The Biggest Loser' that helped explain what set participants who kept the weight off apart from those who gained it back. He spent more than two decades at the National Institutes of Health. His later work on ultraprocessed foods investigated its link to obesity, including one study that demonstrated it actively caused participants to overeat. Hall announced his early retirement and exit from NIH in April, citing censorship of how his research findings were communicated. He's now coauthor of the new book 'Food Intelligence: The Science of How Food Both Nourishes and Harms Us' alongside journalist Julia Belluz. Metabolism and weight loss enter conversations arm in arm, but this, according to Hall, can be reductive. 'I just find it incredibly frustrating sometimes that this idea of metabolism, this really beautiful physiological process that is so fundamental to life, is kind of talked about as, 'Oh well, if you take this supplement, you can boost your metabolism and lose weight,'' he explained to Gupta. Is a faster or higher metabolism really the highway to weight loss? Hall is here to set the record straight, highlighting three misconceptions about metabolism that show there is more to it than meets the eye. Myth 1: People with obesity have slow metabolisms One common belief is that a slower metabolism results in a higher body weight. But mostly, Hall said, the opposite is true. 'Generally, larger people have faster metabolisms than smaller people,' he told Gupta. Hall attributed the pervasiveness of this myth to the way researchers designed early metabolism studies. Scientists initially tried to match up participants' caloric intake to their weight, but they didn't account for the fact that these calorie counts were self-reported. It turned out that those with obesity often underreported the number of calories they ate to a larger degree than their leaner counterparts. This, Hall said, 'led people to a conclusion that, well, if they're eating less calories and they're maintaining their weight, then they must be burning less calories. And maybe the reason why they have obesity is because they have slow metabolisms.' Modern technology now allows researchers to rely on data, not participants' own reports. 'When we actually directly measure people's metabolisms, people with obesity have higher metabolic rates on average than people who are lean,' Hall noted. But the myth that we should be boosting metabolism to treat obesity has stubbornly persisted — and has at times led to deadly consequences. When Stanford University researchers discovered that the chemical compound 2,4-dinitrophenol, or DNP, increased metabolism levels in the 1930s, they enthusiastically promoted it as a safe and effective tool for treating obesity. While DNP did boost metabolism, it also led to side effects that included blindness and death, causing federal drug regulators to quickly withdraw it from the market. 'Maybe,' Hall suggested, 'it shouldn't be too much of a surprise later to realize that with something so fundamentally important to life as metabolism, you can't just turn it up and turn it down with a pharmaceutical drug and not expect some pretty severe side effects, including death.' Myth 2: Metabolism slows down as we age Like weight, age might not affect metabolism as much as you may assume. 'It turns out that until you get to very advanced ages, we're talking 70s and 80s, it looks like our metabolic rate is roughly constant,' Hall said. There are, of course, changes in the aging body that can impact metabolic rates. People 'past the age of 30 or so,' Hall said, are 'tending to lose muscle mass or tending to lose lean mass, and they're tending to gain fat mass. And that alone is anticipated to result in a lower metabolism.' That's because lean muscle burns more calories than fat. But it's these age-related changes — that are not inevitable — and not age itself, that influence one's metabolism. 'Once you get rid of that effect … it doesn't seem like there's a fundamental aging effect to slow metabolism as, as we get older,' Hall concluded. A couple ways to combat the loss of lean muscle mass as you age is by engaging in twice-a-week strength training and getting enough protein in your diet (but no need to go overboard). Myth 3: A high metabolism is necessary for weight loss Another pillar of metabolism mythology is the idea that a slow metabolism is the enemy of continued weight loss. Interventions such as dieting are believed to slow metabolism to the point that you can't lose any additional weight. But keeping your metabolism from slowing down isn't the key to sustained weight loss, Hall said. In fact, it's just the opposite. 'The people who are most successful at losing weight and keeping it off are the ones who sport the slowest metabolisms or the greatest reductions in metabolism,' he said. 'It's kind of like stretching a spring, right?' The more intensely someone diets or exercises, the more weight they'll lose and the more their metabolism will slow down, he explained in his book. Hall's research showed that a slower metabolism 'didn't seem to determine anyone's ability to lose weight or keep it off in the short or long run.' By uncoupling metabolism from the weight loss conversation, Hall said he hopes everyone can appreciate the phenomenon for what it really is. Misinformation about metabolism 'has really distracted people, I think, from the real beauty of what this is,' he told Gupta. 'It's harnessing the continuous flow of matter and energy in our food and in our breath and powering every cell in our body, as well as the bodies and cells of practically every organism that we have ever encountered,' Hall said. 'It's a fundamental component of life, and it's just incredibly fascinating.'
Cision Canada
3 days ago
- Cision Canada
Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep
Key opinion leader event and pancreatic cancer clinical data validate decision to engage with regulators on plans for a registration-enabling study New members of the management team bring expertise in progressing clinical programs and executing successful biotech transactions Translational data further elucidate pelareorep's mechanism of action and ability to prime the tumor microenvironment for treatment Commitment to limiting dilution evidenced by termination of At-the-Market and Equity Line of Credit facilities SAN DIEGO, Aug. 8, 2025 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today reported financial results and recent highlights for the second quarter of 2025. All dollar amounts are expressed in Canadian currency unless otherwise noted. "We have turned the corner from proof-of-concept studies and will be sprinting toward regulatory clarity for the remainder of the year," said Jared Kelly, Chief Executive Officer of Oncolytics. "As we shore up our intellectual property, get a clear registration path for pelareorep, and allow our GOBLET data to mature, we will establish our position as the only platform immunotherapy in gastrointestinal tumors." Poster presentation at the American Society of Clinical Oncology Annual Meeting features translational data further demonstrating pelareorep's mechanism of action. Additional analyses of the combination of pelareorep, gemcitabine, nab-paclitaxel, and atezolizumab in first-line ("1L") metastatic pancreatic ductal adenocarcinoma ("mPDAC") patients enhance the understanding of pelareorep's ability to stimulate the immune system and enable treatment regimens to be effective in a traditionally hostile tumor microenvironment (click here for the PR, click here for the poster). Pelareorep expands reovirus-specific T cells, increases cytokines and chemokines, and increases tumor-infiltrating lymphocytes ("TILs") in the blood. New Chief Executive Officer Jared Kelly and Chief Business Officer Andrew Aromando hired to optimize pelareorep's development path. Both are experienced biotech executives with decades of experience advising companies, advancing clinical programs, and navigating successful transactions. They were both instrumental in guiding the sale of Ambrx Biopharma to Johnson & Johnson. Analyses of clinical data show pelareorep's ability to improve survival, and translational data confirming how the intended benefits are achieved. Recently highlighted survival data in mPDAC and breast cancer point to meaningful survival benefits for patients treated with pelareorep-based regimens compared to either control arms or historical data (click here for the PR). In 1L mPDAC, a review of landmark studies shows a historical benchmark of 9.2% two-year survival for chemotherapy regimens, in contrast to the 21.9% two-year survival rate recorded for 100 patients receiving pelareorep and chemotherapy. Translational data from multiple studies and tumor types provide evidence as to how these impressive results have been achieved (click here for the PR). In the GOBLET and AWARE-1 studies, pelareorep converted immunologically "cold" tumors to "hot" ones as a result of the upregulation of interferons, CXCL9/10/11, and PD-L1 in addition to the expansion and mobilization of TILs in the blood, which is correlated with a reduction in tumor size. Key Opinion Leader ("KOL") webinar discussion solidifies pelareorep's opportunity in mPDAC and other gastrointestinal cancers. Presentations from KOLs and a roundtable discussion of pelareorep's clinical data in mPDAC and gastrointestinal cancers point to a potentially significant opportunity for an immunotherapeutic drug candidate that already has shown the ability to extend survival for patients (click here for the PR). Specifically, 1L mPDAC would be ideal for pelareorep as there are no immunotherapies approved for that line of treatment, multiple 1L studies have already demonstrated pelareorep's ability to improve survival in that patient population, and it is backed up by translational data showing the ability to activate the immune system and alter the tumor microenvironment so it is more amenable to therapeutic intervention. Strategic decision to pursue registration-enabling pivotal study for pelareorep in 1L mPDAC. Discussions with regulators are underway to finalize the approval pathway for pelareorep in 1L mPDAC (click here for the PR). This includes decisions on which treatment regimens will be involved, whether to collaborate with a third party on the study, and formalizing overall survival as the primary endpoint. The prioritization of the pancreatic cancer program is based on the compelling survival and translational data from previous studies involving over 100 patients, and the particularly high unmet medical need in this indication. Pelareorep has already received Fast Track and Orphan Drug designation from the U.S. Food and Drug Administration (the "FDA") for mPDAC. If discussions with regulators proceed as expected and the feedback is positive, start-up activities for the study are expected to commence as early as Q4 2025. Commitment to limiting dilutive financing and maximizing shareholder value. Oncolytics intends to terminate its At-the-Market financing facility with Cantor Fitzgerald and Equity Line of Credit with Alumni Capital. The Company believes it has sufficient capital to reach critical regulatory and clinical milestones this fall and pursue strategic opportunities that demonstrate pelareorep's potential without the need for near-term dilutive financings at this time. Additionally, as separately announced, the Company has given formal notice to delist from the Toronto Stock Exchange (the "TSX"). Once delisted from the TSX, the Company's common shares will continue to trade under the symbol "ONCY" on the Nasdaq. Financial Highlights As of June 30, 2025, the Company reported $14.6 million in cash and cash equivalents, projecting a cash runway through key milestones and into the first quarter of 2026. The net loss for the second quarter of 2025 was $6.2 million, compared to a net loss of $7.3 million for the second quarter of 2024. The basic and diluted loss per share was $0.07 in the second quarter of 2025, compared to a basic and diluted loss per share of $0.10 in the second quarter of 2024. Research and development ("R&D") expenses for the second quarter of 2025 were $2.8 million, compared to $4.6 million for the second quarter of 2024. The decrease was primarily attributable to lower clinical trial expenses as the Company focused its R&D efforts on Cohort 5 of the GOBLET study, which is supported by the Pancreatic Cancer Action Network ("PanCAN") Therapeutic Accelerator Award. General and administrative expenses for the second quarter of 2025 were $2.9 million, compared to $3.4 million for the second quarter of 2024. The decrease was primarily due to lower public company-related expenses, and partially offset by higher personnel-related expenses associated with changes to the management team. Net cash used in operating activities for the six months ended June 30, 2025, was $12.0 million, compared to $14.3 million for the six months ended June 30, 2024. The decrease reflected lower operating activities in 2025, partially offset by higher non-cash working capital changes. Anticipated Milestones Q3 2025: Provide an updated clinical timeline for the registration-enabling pivotal study for pelareorep in 1L mPDAC. As early as Q4 2025: Initiate start-up activities for the registration-enabling study for pelareorep in 1L mPDAC. End of 2025: Updated clinical data regarding safety and efficacy in Cohort 4 of the GOBLET study investigating pelareorep combined with atezolizumab in anal carcinoma. Q4 2025: Initial responses from the U.S. Patent and Trademark Office ("PTO") regarding the company's application to extend patent protection for pelareorep. Annual General Meeting and Conference Call Change Management is hosting the Annual General Meeting later today at 10:00 a.m. ET, August 8, 2025. Oncolytics' Chief Executive Officer, Jared Kelly, will provide a brief update after the formal portion of the meeting. To access the meeting as a guest (i.e., a non-voting shareholder): Visit the webcast site: Click the button "I am a Guest" and complete the form If necessary, provide the case-sensitive password: onc2025 Information on how to vote your shares by proxy and attend the meeting as a shareholder is available in the Company's most recent Management Information Circular (the "Circular") dated June 18, 2025. The Circular is available on the Reports page of the investor relations section of the Company's website at and in Canadian and American securities filings. Going forward, Oncolytics will continue to announce quarterly financial results via press releases and in securities filings, but will no longer host quarterly conference calls with the management team. As at June 30, 2025 December 31, 2024 Assets Current assets Cash and cash equivalents $ 14,626 $ 15,942 Other receivables 72 68 Prepaid expenses 3,174 1,885 Warrant derivative 1,024 980 Total current assets 18,896 18,875 Property and equipment 351 411 Right-of-use assets 727 901 Total assets $ 19,974 $ 20,187 Liabilities and Shareholders' Equity Current liabilities Accounts payable and accrued liabilities $ 5,285 $ 4,792 Other liabilities 982 1,618 Lease liabilities 291 277 Total current liabilities 6,558 6,687 Contract liability 6,730 6,730 Lease liabilities 597 787 Total liabilities 13,885 14,204 Commitments Shareholders' equity Share capital Authorized: unlimited Issued: June 30, 2025 – 97,407,903 December 31, 2024 – 80,020,131 451,142 438,193 Contributed surplus 44,792 44,542 Accumulated other comprehensive income 720 961 Accumulated deficit (490,565) (477,713) Total shareholders' equity 6,089 5,983 Total liabilities and shareholders' equity $ 19,974 $ 20,187 ONCOLYTICS BIOTECH INC. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (unaudited) (in thousands of Canadian dollars) Share Capital Contributed Surplus Accumulated Other Comprehensive Income Accumulated Deficit Total As at December 31, 2023 $ 430,906 $ 42,116 $ 544 $ (446,003) $ 27,563 Net loss and other comprehensive income — — 178 (14,150) (13,972) Issued pursuant to incentive share award plan 3 (3) — — — Issued pursuant to "At the Market" Agreement 3,840 — — — 3,840 Share issue costs (202) — — — (202) Share-based compensation expense — 1,082 — — 1,082 As at June 30, 2024 $ 434,547 $ 43,195 $ 722 $ (460,153) $ 18,311 As at December 31, 2024 $ 438,193 $ 44,542 $ 961 $ (477,713) $ 5,983 Net loss and other comprehensive loss — — (241) (12,852) (13,093) Issued pursuant to incentive share award plan 1,481 (1,481) — — — Issued pursuant to "At the Market" Agreement 8,714 — — — 8,714 Issued pursuant to share purchase agreement 3,841 — — — 3,841 Share issue costs (1,087) — — — (1,087) Share-based compensation expense — 1,731 — — 1,731 As at June 30, 2025 $ 451,142 $ 44,792 $ 720 $ (490,565) $ 6,089 Six Months Ended June 30, 2025 2024 Operating Activities Net loss for the period $ (12,852) $ (14,150) Depreciation - property and equipment 51 56 Depreciation - right-of-use-assets 140 165 Share-based compensation expense 1,731 1,082 Interest expense on lease liabilities 74 57 Unrealized foreign exchange loss (gain) 1 (576) Change in fair value of warrant derivative (44) (1,104) Net change in non-cash working capital (1,070) 182 Cash used in operating activities (11,969) (14,288) Investing Activities Acquisition of property and equipment — (201) Cash used in investing activities — (201) Financing Activities Proceeds from "At the Market" equity distribution agreement, net 8,386 3,638 Proceeds from share purchase agreement, net 3,082 — Payment of lease liabilities (205) (168) Cash provided by financing activities 11,263 3,470 Decrease in cash and cash equivalents (706) (11,019) Cash and cash equivalents, beginning of period 15,942 34,912 Impact of foreign exchange on cash and cash equivalents (610) 957 Cash and cash equivalents, end of period $ 14,626 $ 24,850 About Oncolytics Biotech Inc. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies in metastatic breast cancer and early-phase studies in anal and colorectal cancer. It induces anti-cancer immune responses by converting immunologically "cold" tumors "hot" through the activation of innate and adaptive immune responses. The Company is advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors in metastatic pancreatic and breast cancers, both of which have received Fast Track designation from the FDA, and other gastrointestinal tumors. Oncolytics is actively pursuing strategic partnerships to accelerate development and maximize commercial impact. For more about Oncolytics, please visit: or follow the Company on social media on LinkedIn and on X @ oncolytics. Forward-looking statements This press release contains forward-looking statements, within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as "forward-looking statements"). Forward-looking statements contained in this press release include statements regarding Oncolytics' belief as to the potential, mechanism of action and benefits of pelareorep as a cancer therapeutic; its upcoming milestones; its belief that we will establish our position as the only platform immunotherapy in gastrointestinal tumors; its plans for a potential registration-enabling pivotal study in 1L mPDAC; the anticipated potential timing of commencement of start-up activities and enrollment in a study; the focus of its discussions with the FDA in respect of the study; the anticipated trial design; its plan to delist from the Toronto Stock Exchange; its plans with respect to shareholder communications; and its plan to continue actively pursuing strategic partnerships; its goals, strategies and objectives; its belief in the clinical promise of pelareorep in mPDAC and other gastrointestinal cancers; financial projections and the sufficiency of capital to reach critical milestones and pursue strategic opportunities and its need for near-term dilutive financing. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. These statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those anticipated. These risks include, but are not limited to, regulatory outcomes, trial execution, financial resources, access to capital markets, and market dynamics. Please refer to Oncolytics' public filings with securities regulators in the United States and Canada for more information. The Company assumes no obligation to update forward-looking statements, except as required by law. Company Contact Jon Patton Director of IR & Communication [email protected] Investor Relations for Oncolytics Mike Moyer LifeSci Advisors +1-617-308-4306 [email protected]
